Valuation: NeoGenomics, Inc.

Market Cap 2.04B 1.77B 1.65B 1.52B 2.86B 195B 2.91B 19.48B 7.63B 96.74B 7.66B 7.49B 325B P/E 2026 *
-53.6x
P/E 2027 * -63.5x
Enterprise Value 2.04B 1.77B 1.65B 1.52B 2.86B 195B 2.91B 19.48B 7.63B 96.74B 7.66B 7.49B 325B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.31x
Free-Float
97.46%
Yield 2026 *
-
Yield 2027 * -
1 day+3.99%
1 week+11.52%
Current month+8.84%
1 month+8.84%
3 months+71.49%
6 months+31.67%
Current year+35.03%
1 week 13.05
Extreme 13.05
16.17
1 month 13.05
Extreme 13.05
16.17
Current year 7.06
Extreme 7.065
16.17
1 year 4.72
Extreme 4.72
16.17
3 years 4.72
Extreme 4.72
21.22
5 years 4.72
Extreme 4.72
54.74
10 years 4.72
Extreme 4.72
61.57
Manager TitleAgeSince
Chief Executive Officer 65 2025-03-31
Director of Finance/CFO 57 2026-03-01
President 53 2025-03-31
Director TitleAgeSince
Chairman 64 2021-10-06
Director/Board Member 63 2017-07-18
Director/Board Member 69 2020-07-14
Date Insider Type Main position Quantity % Market Cap.
6/23/26 Free

Director

23,909 0.0184%
6/1/26 Fiscal year

Director

73,193 0.0562%
6/1/26 Fiscal year

Chairman

73,193 0.0562%
Change 5-day change 1-year change 3-year change Capi.($)
+3.99%+11.52%+211.37%-8.00% 2.04B
+6.24%+1.88%+91.30%+487.75% 38.62B
+2.73%+8.42%+19.56%+47.00% 25.53B
-2.84%+5.10%-21.08%-37.81% 7.79B
-1.07%+2.80%+10.58%+93.07% 4.93B
+1.04%+12.44%+22.42%+63.09% 3.29B
+8.28%+8.80%-33.38%+865.83% 2.05B
-1.02%+0.11%-12.56%-62.32% 1.86B
+0.83%+2.35%+16.71%+5.34% 1.82B
-2.92%-1.27%+2.84%-33.25% 1.47B
Average +1.52%+3.15%+30.78%+142.07% 8.94B
Weighted average by Cap. +3.43%+2.28%+48.78%+246.21%

Financials

2026 *2027 *
Net sales 804M 698M 649M 598M 1.13B 76.77B 1.15B 7.68B 3.01B 38.13B 3.02B 2.95B 128B 885M 769M 714M 658M 1.24B 84.47B 1.26B 8.45B 3.31B 41.95B 3.32B 3.25B 141B
Net income -38.73M -33.64M -31.24M -28.81M -54.27M -3.7B -55.25M -370M -145M -1.84B -145M -142M -6.18B -33.19M -28.83M -26.77M -24.69M -46.5M -3.17B -47.34M -317M -124M -1.57B -125M -122M -5.29B
Net Debt - -
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
2,500
Date Price Change Volume
26-07-30 US$15.88 +3.99% 5,303,452
26-07-29 US$15.27 +13.96% 8,432,251
26-07-28 US$13.40 +1.98% 2,402,643
26-07-27 US$13.14 -5.40% 1,795,795
26-07-24 US$13.89 -2.46% 1,992,873
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
15.88USD
Average target price
19.72USD
Spread / Average Target
+24.20%

Quarterly revenue - Rate of surprise